GSK recalls OTC weight-loss drug alli

Share this article:

GSK announced Thursday that it is voluntarily recalling its weight-loss product, alli, from US and Puerto Rico retail locations due to product-tampering concerns.

The drugmaker said in a statement that it is conducting an investigation with the FDA following inquiries from consumers about bottles of alli that contained “tablets and capsules that were not alli.”

“Safety is our first priority and we are asking retailers and pharmacies to remove all alli from their shelves immediately. We have posted a Consumer Alert on our website, www.myalli.com" President of GSK Consumer Healthcare North America Colin Mackenzie said in a statement.

Consumers who purchased the product are advised to call GSK at 800-671-2554 for a representative who will provide further instruction.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.